focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 3-UK steps vaccinations as COVID surges, worst weeks still to come

Mon, 11th Jan 2021 07:42

(Adds more quotes)

By Michael Holden

LONDON, Jan 11 (Reuters) - Britain is facing the worst weeks
of the COVID-19 pandemic, its chief medical officer said on
Monday, with the health service facing a "dangerous time" as
deaths and cases hit record highs before the rollout of a mass
vaccination programme.

Deaths from the virus have now exceeded 81,000 in the United
Kingdom - the world's fifth-highest toll - with more than 3
million people testing positive. A new, more transmissible
variant of the disease is surging through the population, with
one in 20 people in parts of London now infected.

In a bid to get on top of the pandemic and to try to restore
some degree of normality by the spring, Britain is rushing out
its largest ever vaccination programme, with shots to be offered
to all those in its top four priority categories - about 15
million people - by the middle of next month.

But the government's chief medical adviser Chris Whitty
warned the situation would deteriorate in the meantime.

"The next few weeks are going to be the worst weeks of this
pandemic in terms of numbers into the NHS (National Health
Service)," he said.

"Anybody who is not shocked by the number of people in
hospital who are seriously ill at the moment and who are dying
over the course of this pandemic, I think, has not understood
this at all. This is an appalling situation," he told BBC TV.

"SIGNIFICANT CRISIS"

During the peak of the first outbreak in April, about 18,000
people were in hospital but now there are 30,000, Whitty said,
adding the health service was facing "a significant crisis".

"Everybody says that this is the most dangerous time we've
really had in terms of numbers into the NHS," he said.

On Friday, London's mayor said the British capital's
hospitals were in danger of being overwhelmed by COVID patients,
and ministers and health chiefs have pleaded with people to
respect lockdown measures and stay at home unless it was
essential to go out.

The government is pinning its hopes on a mass vaccination
programme to offer a way out of the pandemic by the spring.

Britain was the first country to approve vaccines developed
by Oxford-AstraZeneca and by Pfizer/BioNTech
, and on Friday approved Moderna's shot. It
is aiming to offer shots to 15 million people by the middle of
next month.

To reach that target, which will require delivering 2
million vaccines a week, the government is opening seven big
vaccination centres while additional doctors' surgeries,
hospitals and some pharmacies will also start delivering shots.

"The vaccinations are really beginning to ramp up, 200,000 a
day, we've done an incredible job this past week," Nadhim
Zahawi, the minister in charge of the vaccination programme,
told Sky News

Those in the four highest risk levels, including those over
70, the most clinically vulnerable and frontline health workers,
will be offered the vaccines by February 15, he said.

"We are now very close to the point, with the vaccinations,
where we are able to get on top of this, but it is not yet,"
Whitty said.

There have been calls for the government to take tougher
action against those who break the lockdown rules, but Zahawi
said ministers did not want to "go any tougher" although
existing measures might be more tightly enforced.

"These rules are not boundaries to be pushed against," he
said. "What we need is people to behave as if they've got the
virus and so that we can bring this virus under control whilst
we vaccinate."
(Additional reporting by Kate Holton, William Schomberg and
James Davey; writing by Michael Holden; editing by Estelle
Shirbon, Guy Faulconbridge and Angus MacSwan)

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 09:41

LONDON BROKER RATINGS: Deutsche Bank starts Deliveroo at 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
12 Feb 2024 09:12

Barclays sees "compelling" entry point at AstraZeneca after recent falls

(Sharecast News) - Barclays has kept an 'overweight' position on AstraZeneca despite the biopharma group's disappointing annual results last week, saying that the stock's recent underperformance provides an attractive entry point for investors.

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
9 Feb 2024 07:51

LONDON BRIEFING: Barclays buys Tesco's retail banking business

(Alliance News) - Stocks in London are called to open higher on Friday, closing off a busy corporate week.

Read more
8 Feb 2024 17:00

LONDON MARKET CLOSE: Softer earnings weigh on underperforming FTSE 100

(Alliance News) - London's FTSE 100 ended lower on Thursday, with mixed corporate updates keeping a lid on enthusiasm, while in New York the S&P 500 has the 5,000 point mark in touching distance.

Read more
8 Feb 2024 14:42

London close: Stocks slip as US jobless claims fall

(Sharecast News) - London markets experienced a downturn in trading on Thursday, with stocks relinquishing earlier gains as investors processed a decrease in jobless claims in the United States.

Read more
8 Feb 2024 12:08

LONDON MARKET MIDDAY: DS Smith surges on takeover approach from Mondi

(Alliance News) - Stock prices in London were mixed at midday Thursday, as markets struggled to find direction amid a mixed wave of corporate updates and earnings.

Read more
8 Feb 2024 08:59

LONDON MARKET OPEN: Unilever up on buyback; BAT ups dividend

(Alliance News) - THE FTSE 100 in London opened slightly higher on Thursday, with earnings from British American Tobacco and Unilever boosting the index.

Read more
8 Feb 2024 08:44

TOP NEWS: AstraZeneca confident after 2023 profit more than doubles

(Alliance News) - AstraZeneca PLC on Thursday said it expects another year of strong growth after reporting pretax profit in 2023 more than doubled.

Read more
8 Feb 2024 07:58

AstraZeneca shares slip as Q4 profits miss forecasts

(Sharecast News) - Biopharma titan AstraZeneca delivered a 6% increase in sales in 2023 despite a $3.7bn decline in Covid-19 medicines revenues, as it guided to a strong pick-up in growth this year - though profits came in slightly under analysts' forecasts.

Read more
8 Feb 2024 07:50

LONDON BRIEFING: Unilever sets new buyback; Astra profit surges

(Alliance News) - Stocks in London are called to open slightly higher on Thursday, as investors eye a busy day of earnings.

Read more
2 Feb 2024 08:38

AstraZeneca celebrates latest successful trial of acoramidis in Japan

(Alliance News) - AstraZeneca PLC on Friday said positive results from a Phase 3 trial of acoramidis are consistent with global findings, bring the drug closer to regulatory submission in Japan.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.